Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2004-9-10
pubmed:abstractText
Patients with cystic fibrosis (CF) exhibit an excessive host inflammatory response. The aim of this study was to determine (i) whether interleukin 8 (IL-8) secretion is increased from monocytes from subjects heterozygous as well as homozygous for cystic fibrosis transmembrane conductance regulator (CFTR) mutations and (ii) whether this is due to increased cell surface lipopolysaccharide (LPS) receptors or, alternatively, increased activation of mitogen-activated protein kinases (MAPK). The basal level of IL-8 secretion was higher from monocytes from CF patients than from monocytes from healthy controls (P = 0.02) and obligate heterozygotes (parents of the CF patients). The 50% effective concentrations for LPS-induced IL-8 production for monocytes from both CF patients and obligate heterozygotes were 100-fold lower than those for monocytes from healthy controls (P < 0.05). No differences in the levels of IL-1beta production were seen between these groups. Expression of the LPS surface receptors CD14 and Toll-like receptor 4 were not different between CF patients and healthy controls. In contrast, phosphorylation of the MAPKs p38 and ERK occurred at lower doses of LPS in monocytes from patients heterozygous and homozygous for CFTR mutations. These results indicate that a single allelic CFTR mutation is sufficient to augment IL-8 secretion in response to LPS. This is not a result of increased LPS receptor expression but, rather, is associated with alterations in MAPK signaling.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/15358638-10390398, http://linkedlifedata.com/resource/pubmed/commentcorrection/15358638-10400842, http://linkedlifedata.com/resource/pubmed/commentcorrection/15358638-10433940, http://linkedlifedata.com/resource/pubmed/commentcorrection/15358638-10725749, http://linkedlifedata.com/resource/pubmed/commentcorrection/15358638-10772660, http://linkedlifedata.com/resource/pubmed/commentcorrection/15358638-10875853, http://linkedlifedata.com/resource/pubmed/commentcorrection/15358638-10919974, http://linkedlifedata.com/resource/pubmed/commentcorrection/15358638-10931414, http://linkedlifedata.com/resource/pubmed/commentcorrection/15358638-11025834, http://linkedlifedata.com/resource/pubmed/commentcorrection/15358638-11257452, http://linkedlifedata.com/resource/pubmed/commentcorrection/15358638-1717947, http://linkedlifedata.com/resource/pubmed/commentcorrection/15358638-2475911, http://linkedlifedata.com/resource/pubmed/commentcorrection/15358638-7524148, http://linkedlifedata.com/resource/pubmed/commentcorrection/15358638-7697234, http://linkedlifedata.com/resource/pubmed/commentcorrection/15358638-8217192, http://linkedlifedata.com/resource/pubmed/commentcorrection/15358638-8520783, http://linkedlifedata.com/resource/pubmed/commentcorrection/15358638-8632940, http://linkedlifedata.com/resource/pubmed/commentcorrection/15358638-9041336, http://linkedlifedata.com/resource/pubmed/commentcorrection/15358638-9363938, http://linkedlifedata.com/resource/pubmed/commentcorrection/15358638-9389746, http://linkedlifedata.com/resource/pubmed/commentcorrection/15358638-9393813, http://linkedlifedata.com/resource/pubmed/commentcorrection/15358638-9435559, http://linkedlifedata.com/resource/pubmed/commentcorrection/15358638-9616231, http://linkedlifedata.com/resource/pubmed/commentcorrection/15358638-9725921, http://linkedlifedata.com/resource/pubmed/commentcorrection/15358638-9725922, http://linkedlifedata.com/resource/pubmed/commentcorrection/15358638-9736040
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1071-412X
pubmed:author
pubmed:issnType
Print
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
819-24
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed-meshheading:15358638-Adult, pubmed-meshheading:15358638-Antigens, CD14, pubmed-meshheading:15358638-Case-Control Studies, pubmed-meshheading:15358638-Cystic Fibrosis Transmembrane Conductance Regulator, pubmed-meshheading:15358638-Female, pubmed-meshheading:15358638-Heterozygote, pubmed-meshheading:15358638-Humans, pubmed-meshheading:15358638-Interleukin-8, pubmed-meshheading:15358638-MAP Kinase Signaling System, pubmed-meshheading:15358638-Male, pubmed-meshheading:15358638-Membrane Glycoproteins, pubmed-meshheading:15358638-Middle Aged, pubmed-meshheading:15358638-Monocytes, pubmed-meshheading:15358638-Mutation, pubmed-meshheading:15358638-Prospective Studies, pubmed-meshheading:15358638-Receptors, Cell Surface, pubmed-meshheading:15358638-Toll-Like Receptor 4, pubmed-meshheading:15358638-Toll-Like Receptors
pubmed:year
2004
pubmed:articleTitle
Interleukin 8 secretion from monocytes of subjects heterozygous for the deltaF508 cystic fibrosis transmembrane conductance regulator gene mutation is altered.
pubmed:affiliation
Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't